9.12
前日終値:
$9.24
開ける:
$9.3
24時間の取引高:
266.14K
Relative Volume:
0.86
時価総額:
$470.78M
収益:
$227.18M
当期純損益:
$24.38M
株価収益率:
19.10
EPS:
0.4774
ネットキャッシュフロー:
$53.60M
1週間 パフォーマンス:
+3.40%
1か月 パフォーマンス:
+14.29%
6か月 パフォーマンス:
+21.76%
1年 パフォーマンス:
+73.71%
Puma Biotechnology Inc Stock (PBYI) Company Profile
名前
Puma Biotechnology Inc
セクター
電話
(424) 248-6500
住所
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology Inc
|
9.12 | 470.26M | 227.18M | 24.38M | 53.60M | 0.4774 |
|
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-28 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Underperform |
| 2019-10-08 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-10 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-01-17 | 開始されました | Leerink Partners | Mkt Perform |
| 2019-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-11-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-11-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 開始されました | Goldman | Sell |
| 2018-05-11 | 繰り返されました | Stifel | Buy |
| 2017-11-10 | 繰り返されました | Citigroup | Buy |
| 2017-11-10 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 繰り返されました | Stifel | Buy |
| 2017-09-11 | 繰り返されました | Credit Suisse | Outperform |
| 2017-07-10 | 再開されました | Leerink Partners | Outperform |
| 2017-06-06 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 繰り返されました | RBC Capital Mkts | Sector Perform |
すべてを表示
Puma Biotechnology Inc (PBYI) 最新ニュース
Puma (PBYI) Latest Quarter: The Available Earnings Metric Delivers a Beat; Investor Response: The Stock Ends Down 4.00% for the Current SessionEarnings Turnaround - vinanet.vn
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - AOL.com
Puma (PBYI) Latest Quarter: EPS Lands Above Forecast in the Current Update; Trading Move: Shares Move 4.76% Up in the Latest SessionEPS Growth Report - vinanet.vn
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - MarketBeat
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance
Puma Biotechnology, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-08-10 - Seeking Alpha
Puma Biotechnology Reports $56.5M Revenue and Profitability in Q2 - sekbernews.id
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades - Sahm
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Puma Biotech earnings beat by $0.16, revenue topped estimates - Investing.com Nigeria
TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock - marketbeat.com
Transcript : Puma Biotechnology, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Yahoo Finance
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares - Investing.com
Puma Biotechnology Q2 Earnings Call Highlights - MarketBeat
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ... - finance.yahoo.com
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns - Investing.com
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotech: Q2 Earnings Snapshot - aol.com
PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary - TradingView
Puma Biotechnology Reports Second Quarter 2026 Financial Results - marketscreener.com
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Finviz
Puma Biotechnology Inc expected to post earnings of 4 cents a shareEarnings Preview - TradingView
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Puma Biotechnology (PBYI) Gains 1.43% to $7.8, Holds Above Key Support at $7.41PCR Mean Reversion - dars.gov.et
Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI - MarketBeat
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline - Yahoo Finance
Puma Biotechnology (PBYI) Slips 1.88% as Stock Tests Key Support LevelsSMA Signal - dars.gov.et
Puma Biotechnology Inc Revenue Breakdown – NASDAQ:PBYI - TradingView
Puma Biotechnology Inc (PBYI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Puma Biotechnology Inc (PBYI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ETFs Investing in Puma Biotechnology, Inc. Stocks - TradingView
PBYI|Puma Biotechnology Inc|Price:7.980|Chg%:-0.030 - TradingKey
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results - WBOC TV
Puma Stock Puma Biotechnology Inc Discount Puma Biotechnology Acquisition Outlet Online PUMA Biotechnology Form S - มูลนิธิเพื่อผู้บริโภค มพบ.
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares By Investing.com - Investing.com Nigeria
Puma biotechnology CFO Maximo Nougues sells $77,556 in stock By Investing.com - Investing.com South Africa
Form 4 Puma Biotechnology Inc For: 8 July By Investing.com - Investing.com Nigeria
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com - Investing.com South Africa
Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan
Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 - Investing.com
Form 144 PUMA BIOTECHNOLOGY For: 6 July By Investing.com - Investing.com Nigeria
[144] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology (PBYI) Faces Resistance as Shares Pull Back Toward Key SupportMarket Neutral Pair - dars.gov.et
Price to sales forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
Puma Biotechnology Inc (PBYI) 財務データ
収益
当期純利益
現金流量
EPS
Puma Biotechnology Inc (PBYI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HUNT DOUGLAS M | See Remarks |
Jul 06 '26 |
Sale |
8.26 |
8,460 |
69,905 |
196,841 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jul 06 '26 |
Sale |
8.26 |
9,386 |
77,557 |
230,637 |
大文字化:
|
ボリューム (24 時間):